SCHEMBL5016170

SCHEMBL5016170

O=C(Nc1cc(-n2cccn2)nc(-c2ccco2)n1)C1CCCC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 14/20 0.73
ADORA1 P30542 13/20 0.73
ADORA3 P0DMS8 7/20 0.63
ADORA2B P29275 6/20 0.63
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
USP2 O75604 1/20 0.48
HSD17B10 Q99714 1/20 0.48
ALDH1A1 P00352 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
HPGD P15428 1/20 0.47
KDM4E B2RXH2 2/20 0.44
POLB P06746 2/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
PKM P14618 1/20 0.44
KMT2A Q03164 1/20 0.44
GSK3B P49841 1/20 0.43
MAPK14 Q16539 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5016270 0.99 ADORA2A (0.71) ADORA2AADORA1ADORA3ADORA2BNPC1
SCHEMBL5016135 0.98 ADORA2A (0.73) ADORA2AADORA1ADORA3ADORA2BNPC1
SCHEMBL5017668 0.96 ADORA2A (0.76) ADORA2AADORA1ADORA3ADORA2BNPC1
SCHEMBL5016222 0.87 ADORA2A (0.69) ADORA2AADORA1ADORA3ADORA2BNPC1
SCHEMBL5016065 0.85 ADORA2A (0.82) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL5016114 0.85 ADORA2A (0.67) ADORA2AADORA1ADORA3ADORA2BNPC1
SCHEMBL5017677 0.84 ADORA2A (1.00) ADORA2AADORA1ADORA3ADORA2B
SCHEMBL5612886 0.84 ADORA2A (0.80) ADORA2AADORA1ADORA3ADORA2BHSD17B10
SCHEMBL8287644 0.84 ADORA2A (0.65) ADORA2AADORA1ADORA3ADORA2B
SCHEMBL5017742 0.83 ADORA2A (0.66) ADORA2AADORA1ADORA3ADORA2BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US claimed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
EP-1697351-A1 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma AG (CH) 2006-09-06 EP disclosed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.